Catalyst Dossier · compiled by CeliA 🧫
Bolt Biotherapeutics, Inc. (BOLT)
Pharmaceutical Preparations · market cap $11M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-05-15 (est.)
Phase 2
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Bolt Biotherapeutics (BOLT) is a micro-cap clinical-stage pharmaceutical company with a market cap of approximately $9M and roughly 40 employees. Its sole disclosed pipeline asset is BDC-4182, currently in Phase 2 for metastatic gastric/gastroesophageal adenocarcinoma. The company holds $11.6M in cash against a runway of only ~4.3 months, making near-term financing an existential priority.
The catalyst path
- 2027-05-15 (est.)Phase 2 · BDC-4182imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| BDC-4182 | Phase 2 | Gastric Cancer Adenocarcinoma Metastatic |
Price & technical context
3-month
+13.1%
6-month
-5.9%
12-month
-48.6%
52-wk range
$4.51–$12.32
vs 50-day MA
+9.3%
vs 200-day MA
-5.3%
Realized vol
66.6%
Max drawdown
-85.0%
Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BOLT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.